全文获取类型
收费全文 | 15094篇 |
免费 | 1414篇 |
国内免费 | 886篇 |
专业分类
耳鼻咽喉 | 138篇 |
儿科学 | 135篇 |
妇产科学 | 380篇 |
基础医学 | 1405篇 |
口腔科学 | 256篇 |
临床医学 | 1881篇 |
内科学 | 2632篇 |
皮肤病学 | 140篇 |
神经病学 | 876篇 |
特种医学 | 599篇 |
外国民族医学 | 6篇 |
外科学 | 1600篇 |
综合类 | 2472篇 |
现状与发展 | 3篇 |
预防医学 | 845篇 |
眼科学 | 252篇 |
药学 | 1164篇 |
21篇 | |
中国医学 | 1158篇 |
肿瘤学 | 1431篇 |
出版年
2024年 | 90篇 |
2023年 | 1297篇 |
2022年 | 1825篇 |
2021年 | 1722篇 |
2020年 | 1720篇 |
2019年 | 786篇 |
2018年 | 418篇 |
2017年 | 490篇 |
2016年 | 561篇 |
2015年 | 630篇 |
2014年 | 1240篇 |
2013年 | 930篇 |
2012年 | 939篇 |
2011年 | 808篇 |
2010年 | 740篇 |
2009年 | 575篇 |
2008年 | 409篇 |
2007年 | 456篇 |
2006年 | 286篇 |
2005年 | 193篇 |
2004年 | 147篇 |
2003年 | 127篇 |
2002年 | 114篇 |
2001年 | 140篇 |
2000年 | 97篇 |
1999年 | 116篇 |
1998年 | 120篇 |
1997年 | 74篇 |
1996年 | 64篇 |
1995年 | 77篇 |
1994年 | 40篇 |
1993年 | 35篇 |
1992年 | 27篇 |
1991年 | 21篇 |
1990年 | 16篇 |
1989年 | 20篇 |
1988年 | 22篇 |
1987年 | 6篇 |
1986年 | 4篇 |
1985年 | 1篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1968年 | 1篇 |
1958年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 390 毫秒
71.
《Journal of infection and chemotherapy》2019,25(6):470-472
We herein report a case of Klebsiella pneumoniae (K. pneumoniae) spondylitis and bacteremia in a 90-year-old man with diabetes mellitus who had undergone sigmoidectomy and had a fecalith. Two months prior to admission, he had received antimicrobial treatment for 2 weeks for K. pneumoniae bacteremia whose entry was unclear and he was readmitted to our hospital owing to fever and stomachache. K. pneumoniae was isolated from two sets of blood cultures, and computed tomography and magnetic resonance imaging revealed inflammation and destruction of the 8th and 9th thoracic vertebra. The diagnosis was spondylodiscitis secondary to K. pneumoniae bacteremia. Although the entry point for K. pneumoniae was unclear, we suggest that inflammation of the mucosa around the fecalith might have caused the Enterobacteriaceae bacteremia. 相似文献
72.
中药(单体/复方)药效物质基础研究是中医药现代研究的关键问题之一。然而,目前运用的生化和分子生物学方法很难诠释其多靶点、整体性和动态性的整合调节作用。课题组提出的"证治代谢组学"假说理论指出,不同的证候存在"证相关代谢谱群"和"证相关生物标志物",这可能是中药药效物质基础所在,辨证论治后偏离的代谢网络功能呈现回归趋势。基于"证治代谢组学"假说开展中药(单体/复方)药效物质基础研究,这将为阐释中药(单体/复方)防病治病和养生保健的科学内涵及其对疾病个体的整合调节作用提供新的思路。本文以冠心病为研究载体、气阴虚血瘀证为切入点、活血保心丸为干预措施,就该研究思路的内涵与总体模式、提出的背景与依据、实践的方式与可行性、创新与特色及其研究意义等进行了简要介绍。 相似文献
73.
74.
目的探讨补骨脂素抗增生性瘢痕的作用机制。方法体外培养成纤维细胞,按随机数字表法分为正常组(培养正常成纤维细胞)、瘢痕组(培养增生性瘢痕成纤维细胞)、TGF-β1组(10 ng/ml TGF-β1处理增生性瘢痕成纤维细胞5 min^12 h)、Smurf2 RNA干扰组[Smad泛素化调节因子2(Smad ubiquitin regulatory factor2,Smurf2)siRNA转染增生性瘢痕成纤维细胞72 h]、补骨脂素组(10μmol/L补骨脂素处理增生性瘢痕成纤维细胞继续培养72 h)、补骨脂素+TGF-β1组(增生性瘢痕成纤维细胞加入补骨脂素培养72 h后加入TGF-β1培养6 h)。采用Western blot法检测Smurf2、α-平滑肌肌动蛋白(α-actin SMA,α-SMA)蛋白表达;RT-PCR法检测Ⅰ型胶原蛋白mRNA表达;ELISA法检测TGF-β1蛋白分泌。结果与正常组比较,瘢痕组Smurf2蛋白[(0.83±0.08)比(0.38±0.07)]表达增加(P<0.05);与瘢痕组比较,Smurf2 RNA干扰组TGF-β1[(2.2±0.18)比(4.2±0.47)]表达降低(P<0.05);TGF-β1组Smurf2[(0.71±0.06)比(0.42±0.04)]、α-SMA[(1.42±0.12)比(0.91±0.09)]蛋白表达增加(P<0.05),Ⅰ型胶原蛋白mRNA[(0.72±0.09)比(0.41±0.07)]表达增加(P<0.05);补骨脂素组Smurf2[(0.05±0.01)比(0.42±0.04)]、α-SMA[(0.71±0.07)比(0.91±0.09)]蛋白表达降低(P<0.05),Ⅰ型胶原蛋白mRNA表达[(0.12±0.04)比(0.41±0.07)]降低(P<0.05)。结论补骨脂素可能通过TGF-β1/Smurf2信号通路抑制α-SMA蛋白表达,从而降低Ⅰ型胶原蛋白表达,起到抑制瘢痕形成的作用。 相似文献
75.
76.
《Injury》2021,52(3):330-338
BackgroundThe present study aimed to summarize the predictors of acute kidney injury (AKI) in patients after hip surgery.MethodsA literature search was performed using PubMed, EMBASE, Cochrane Library, and Web of Science for studies assessing the predictors of AKI after hip fracture surgery. Pooled odds ratio (OR) and mean difference (MD) of those who experienced AKI compared to those who did not were calculated for each variable. Evidence was assessed using the Newcastle–Ottawa Scale.ResultsTen studies with 34 potential factors were included in the meta-analysis. In the primary analysis, 12 factors were associated with AKI, comprising males (OR 1.25; 95% confidence interval (CI) 1.14–1.36), advanced age (MD 2.28; 95% CI 0.80–3.75), myocardial infarction (OR 1.39; 95% CI 1.18–1.63), hypertension (OR 1.46; 95% CI 1.13–1.89), diabetes (OR 1.84; 95% CI 1.40–2.42), chronic kidney disease (OR 3.66; 95% CI 2.21–6.07), hip arthroplasty (OR 1.35; 95% CI 1.22–1.50), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers use (OR 2.28; 95% CI 1.68–3.08), more intraoperative blood loss (MD 44.06; 95% CI 2.88–85.24), higher preoperative blood urea nitrogen levels (MD 5.29; 95% CI 3.38–7.20), higher preoperative serum creatinine levels (MD 0.4; 95% CI 0.26–0.53), and lower preoperative estimated glomerular filtration rate (MD −19.59; 95% CI −26.92–−12.26). Another 13 factors related to AKI in individual studies were identified in the systematic review.ConclusionRelated prophylaxis strategies should be implemented in patients involved with the above-mentioned characteristics to prevent AKI after hip surgery. 相似文献
77.
彩色多普勒超声在Graves''''病诊断中的作用 总被引:1,自引:0,他引:1
目的:探讨彩色多普勒超声在Graves’病(又称弥漫性甲状腺肿)诊断中的作用。方法:用能量多普勒超声观察40例Graves’病患者及40例正常对照组双侧甲状腺组织的血液供应及分布情况;用脉冲多普勒测量颈总动脉的收缩期峰值流速(VPS),甲状腺上动脉的收缩期峰值流速(VPS)及阻力指数(RI),测量甲状腺上动脉的内径。结果:Graves’病组甲状腺实质内的血供极为丰富,血流分级以Ⅲ级为主,呈“火海征”,Graves’病组与正常对照组相比有显著性差异,P<0.005。Graves’病组颈总动脉的收缩期峰值流速为(162.1±31.5)cm/s,正常对照组颈总动脉的收缩期峰值流速为(98.2±20.9)cm/s,Graves’病组甲状腺上动脉的收缩期峰值流速(108.7±35.6)cm/s,正常对照组甲状腺上动脉的收缩期峰值流速(42.1±15.1)cm/s,以上各参数Graves’病组甲状腺上动脉的阻力指数为0.55±0.11,正常对照组甲状腺上动脉的阻力指数为0.73±0.19。Graves’病组与正常对照组相比有显著性差异P<0.01。Graves’病组甲状腺上动脉的内径为3.34±1.16mm,正常对照组甲状腺上动脉的内径为1.62±1.24mm。Graves’病组与正常对照组相比有显著性差异P<0.01。结论:彩色多普勒超声在Graves’病诊断中有重要的作用。 相似文献
78.
阴沟肠杆菌超广谱β—内酰胺酶、诱导酶的检出与耐药相关性的分析 总被引:8,自引:0,他引:8
目的:了解阴沟肠杆菌超广谱β-内酰胺酶和诱导酶的产生和分布情况。并分析产酶特性和耐药表型的相关性。方法:用纸片扩散确证法和相邻纸片法对104株阴沟肠杆菌进行超广谱β-内酰胺酶及诱导酶的检测,用VITEK全自动药敏分析系统和K-B琼脂扩散法检测其对20种抗生素的耐药性。结果:104例阴沟肠杆菌中,检出超广谱β-内酰胺酶阳性株77株,占74%,诱导酶阳性株26株,占25%,13株两种酶同时阳性。超广谱β-内酰胺酶阳性株主要集中在几个病区,诱导酶阳性株则无此倾向,104株菌对多种怀素高度耐药,产超广谱β-内酰胺酶株的耐药率明显高于非产酶株,产诱导酶株的耐药率反而低于非产酶株。结论:阴沟肠杆菌产酶情况和耐药性均十分严重。多重耐药的主要原因是由于菌株产生超广谱β-内酰胺酶,产酶株对三代头孢的体外敏感试验不能正确反映临床的治疗效果。实验室应加强阴肠杆菌产酶情况的检测,治疗产酶阴沟肠杆菌引起的感染,首选亚胺培南,其次为舒普深,任何情况下应避免使用三代头孢。 相似文献
79.
Betsy D. Kennard Susan G. Silva Simon Tonev Paul Rohde Jennifer L. Hughes Benedetto Vitiello Christopher J. Kratochvil John F. Curry Graham J. Emslie Mark Reinecke John March 《Journal of the American Academy of Child and Adolescent Psychiatry》2009,48(2):186-195
ObjectiveWe examine remission rate probabilities, recovery rates, and residual symptoms across 36 weeks in the Treatment for Adolescents with Depression Study (TADS).MethodThe TADS, a multisite clinical trial, randomized 439 adolescents with major depressive disorder to 12 weeks of treatment with fluoxetine, cognitive–behavioral therapy, their combination, or pill placebo. The pill placebo group, treated openly after week 12, was not included in the subsequent analyses. Treatment differences in remission rates and probabilities of remission over time are compared. Recovery rates in remitters at weeks 12 (acute phase remitters) and 18 (continuation phase remitters) are summarized. We also examined whether residual symptoms at the end of 12 weeks of acute treatment predicted later remission.ResultsAt week 36, the estimated remission rates for intention-to-treat cases were as follows: combination, 60%; fluoxetine, 55%; cognitive–behavioral therapy, 64%; and overall, 60%. Paired comparisons reveal that, at week 24, all active treatments converge on remission outcomes. The recovery rate at week 36 was 65% for acute phase remitters and 71% for continuation phase remitters, with no significant between-treatment differences in recovery rates. Residual symptoms at the end of acute treatment predicted failure to achieve remission at weeks 18 and 36.ConclusionsMost depressed adolescents in all three treatment modalities achieved remission at the end of 9 months of treatment. 相似文献
80.
《European Urology Supplements》2007,6(12):717-722
ObjectivesThe purpose of this review is to discuss the major findings presented at the “New Horizons in Urology” closed expert meeting, held October 2006 in Marbella, Spain, on improving the management of stone disease (renal and ureteral stones), and to summarise the consequences of these findings on improving current practice in managing stone disease.MethodsApproximately 135 European urologists attended the meeting. Data and papers discussed in recent congress meetings in 2006 were considered. Experts in the field of stone disease selected and discussed the most relevant new findings. Furthermore, the delegate's opinion on representative clinical case studies was assessed by interactive voting. An expert panel commented on voting results.ResultsAt the meeting, it was highlighted that stones that fail to pass spontaneously in a reasonable time can be treated by minimally invasive surgical procedures including extracorporeal shock wave lithotripsy (SWL), ureteroscopy (URS), and percutaneous nephrolithotomy (PNL). The choice of treatment largely depends on the size and location of stones. However, treatment with URS is more frequently used for managing stone disease, and the number of SWL therapies is decreasing. Furthermore, the use of α1-adrenoceptor antagonists as medical expulsive therapy has been shown to increase the expulsion rate and decrease the time until the stone is passed.ConclusionsMinimally invasive surgical procedures such as SWL, URS, and PNL have been widely adopted for stone removal, with each approach having its own advantages and disadvantages. 相似文献